TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16730066
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (topical steroid alone)
Study: 11744967
Drug: Intralesional triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intralesional triamcinolone acetonide 5 mg/ml injection
Study: 11744967
Drug: Incision, curettage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incision, curettage and intralesional triamcinolone acetonide injection
Study: 9269010
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg sublingual triazolam
Study: 9269010
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg oral triazolam
Study: 8329825
Drug: Intravenous GHRH(1-29)-NH2
Normalized name: GHRH(1-44)NH2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous GHRH(1-29)-NH2 at 0.25 microgram/kg
Study: 8329825
Drug: Intravenous GHRH(1-29)-NH2
Normalized name: GHRH(1-44)NH2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous GHRH(1-29)-NH2 at 1-2 micrograms/kg
Study: 8329825
Drug: Intranasal GHRH(1-29)-NH2
Normalized name: GHRH(1-44)NH2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal GHRH(1-29)-NH2 at 50 micrograms/kg
Study: 8329825
Drug: Repeated intranasal
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated intranasal GHRH(1-29)-NH2 administration
Study: 21742946
Drug: High-soy diet
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-soy diet (2 servings of soy milk, tofu, or soy nuts, ∼50 mg of isoflavones per day)
Study: 19356389
Drug: Roflumilast 500
Normalized name: ROFLUMILAST 500MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roflumilast 500 microg once daily (Days 1 and 15) + Erythromycin 500 mg three times daily (Days 9 - 21)
Study: 1519573
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (40 mg/day for 4 weeks)
Study: 6470191
Drug: Lithium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium treatment in 21 children
Study: 24262813
Drug: 50mg D-cycloserine
Normalized name: D-(+)-cycloserine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg D-cycloserine administered after each of ten CBT sessions
Study: 24262813
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered after each of ten CBT sessions
Study: 22724029
Drug: Paromomycin (PM)
DrugBank: Paromomycin (DB01421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paromomycin (PM) 20 mg/kg/day for 21 days
Study: 22724029
Drug: Sodium stibogluconate
Normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium stibogluconate (SSG) 20 mg/kg/day for 30 days
Study: 22724029
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PM (15 mg/kg/day) and SSG (20 mg/kg/day) for 17 days
Study: 22724029
Drug: End of
Normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: End of treatment efficacy for PM
Study: 22724029
Drug: End of
Normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: End of treatment efficacy for SSG & PM
Study: 20471234
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of BDP plus montelukast (ML)
Study: 12499890
Drug: ELAD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ELAD therapy
Study: 8915668
Drug: Idarubicin 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarubicin 8 mg/m2/day for 5 days
Study: 8915668
Drug: Rubidazone 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rubidazone 200 mg/m2/day for 4 days
Study: 8915668
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose ARA-C plus m-Amsa
Study: 8915668
Drug: Intensive consolidation
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive consolidation chemotherapy (ICC)
Study: 1670621
Drug: Lymecycline treatment
Normalized name: lymecycline
DrugBank: Lymecycline (DB00256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymecycline treatment for 3 months
Study: 6882615
Drug: Lipid preparation
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid preparation (Diazemuls)
Study: 6882615
Drug: Aqueous preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous preparation (Valium)
Study: 27483064
Drug: Liraglutide (1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (1.8 mg/d via daily subcutaneous injection for 180 days)
Study: 15175566
Drug: Intra-arterial vitamin
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial vitamin C (25 mg/min)
Study: 15175566
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin C (1 g daily)
Study: 10838017
Drug: Ivabradine (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivabradine (multiple dose oral administration every 12 h, eight active dosing levels)
Study: 3766413
Drug: Isosorbide 5‐mononitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide 5‐mononitrate (IS 5‐MN), 40 mg twice daily
Study: 3399285
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose intravenous gamma-globulin (0.6 g/kg every 4 weeks)
Study: 3399285
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose intravenous gamma-globulin
Study: 3399285
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose therapy (not specified in detail)
Study: 31642434
Drug: Calorie-enriched formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calorie-enriched formula milk powder (100 kcal/100 mL)
Study: 31642434
Drug: Normal calorie
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal calorie formula milk powder (67 kcal/100 mL)
Study: 24009294
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors and ARBs (continuation regimen)
Study: 9575601
Drug: Picotamide, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Picotamide, 300 mg t.i.d.
Study: 3049173
Drug: Topical 2%
Normalized name: menthol topical 2% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 2% fenticonazole cream
Study: 3709210
Drug: Topical 2%
Normalized name: menthol topical 2% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 2% miconazole cream
Study: 30477828
Drug: Reminiscence therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reminiscence therapy applied through individual sessions for 8 weeks, with house visits once a week.
Study: 22776634
Drug: Lurasidone 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone 160 mg/d
Study: 24743712
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR 600 mg/d
Study: 22544016
Drug: Escitalopram 20
Normalized name: escitalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 20 mg (started at 10 mg/d, increased to 20 mg/d after 4 weeks)
Study: 15997019
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cognitive-behavioral therapy and fluoxetine hydrochloride
Study: 12622581
Drug: Invasive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive therapy (coronary angiography followed by revascularization if feasible)
Study: 11138536
Drug: Tea ointment
Normalized name: tea tree oil Topical Ointment
DrugBank: Tea leaf (DB10580)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tea ointment
Study: 9178345
Drug: Biofeedback treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback treatment (once a week for a total of four sessions)
Study: 9178345
Drug: Biofeedback treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback treatment (after self-monitoring control period)
Study: 3620275
Drug: Isoxicam, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoxicam, 200 mg once daily
Study: 3620275
Drug: Ketoprofen, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen, 100 mg three times daily
Study: 18311688
Drug: Citalopram (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (0.4 mg/kg body weight, mean 31.96±4.45 mg)
Study: 9084545
Drug: Furosemide 30
Normalized name: furosemide 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 30 mg i.v.
Study: 9084545
Drug: Glycerol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerol 0.5 g/kg i.v.
Study: 30822621
Drug: Docetaxel 100
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 100 mg/m2 + Sorafenib 400 mg bid
Study: 30822621
Drug: Docetaxel 100
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 100 mg/m2 + Placebo
Study: 28946838
Drug: Single 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 5 ml GO-ON injection
Study: 28946838
Drug: Conventional three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional three injections of 2.5 ml GO-ON at weekly intervals
Study: 22394648
Drug: Inhaled budesonide/formoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide/formoterol (200 μg/12 μg)
Study: 22394648
Drug: Inhaled budesonide/salbutamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide/salbutamol (200 μg/200 μg)
Study: 21562990
Drug: Medication review
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication review
Study: 17537096
Drug: No medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medication review
Study: 9701099
Drug: 14-day triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day triple therapy (30 mg of lansoprazole, 1 g of amoxicillin, and 500 mg of clarithromycin twice daily for 14 days)
Study: 9701099
Drug: 10-day triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day triple therapy (30 mg of lansoprazole, 1 g of amoxicillin, and 500 mg of clarithromycin twice daily for 10 days)
Study: 9701099
Drug: Adverse events
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse events related to therapy in 14-day group
Study: 9701099
Drug: Adverse events
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse events related to therapy in 10-day group
Study: 2224165
Drug: IL2 alone
Normalized name: DAB(SUB 389)IL2
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL2 alone or in combination with LAK cells, INF alpha or TNF
Study: 2224165
Drug: IL2 either
Normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL2 either alone or in combination with LAK cells
Study: 445326
Drug: Combination chemotherapy-radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy-radiotherapy (CT)
Study: 445326
Drug: Combination chemotherapy-radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy-radiotherapy with radiation to involved fields (CTIF)
Study: 445326
Drug: Combination chemotherapy-radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy-radiotherapy with total nodal radiation (CTTN)
Study: 445326
Drug: Total nodal
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total nodal radiation followed by chemotherapy (TNCT)
Study: 445326
Drug: Radiation +/−
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation +/− chemotherapy
Study: 25927657
Drug: GlideScope (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: GlideScope (group G, n=35)
Study: 25927657
Drug: GlideScope (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: GlideScope (group G)
Study: 21981988
Drug: No statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No statin treatment (Control)
Study: 21953205
Drug: Medications for
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medications for the treatment of fibromyalgia (specific medications not detailed)
Study: 19217105
Drug: Abdominal massage
Normalized name: PAD,ABDOMINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abdominal massage in addition to prescribed laxatives
Study: 19217105
Drug: Laxatives according
Normalized name: clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Laxatives according to earlier prescriptions
Study: 17441849
Drug: Povidone iodine
Normalized name: POVIDONE IODINE
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone iodine (PVP‐I) 100 mg/ml
Study: 17441849
Drug: Povidone iodine
Normalized name: POVIDONE IODINE
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone iodine (PVP‐I) 70 mg/ml
Study: 17441849
Drug: Chlorhexidine digluconate
Normalized name: Chlorhexidine digluconate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine digluconate 50 mg/ml
Study: 15604328
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg/day for 4 weeks
Study: 7711988
Drug: Simvastatin 10-20
Normalized name: ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Simvastatin 10-20 mg
Study: 2791449
Drug: Oral verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral verapamil (120 mg) and propranolol (80 mg) combined
Study: 3092851
Drug: Oral verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral verapamil (120 mg)
Study: 24203262
Drug: Oral propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral propranolol (80 mg)
Study: 780040
Drug: Ethosuximide given
Normalized name: Ethosuximide
DrugBank: Ethosuximide (DB00593)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethosuximide given once daily
Study: 780040
Drug: Ethosuximide given
Normalized name: Ethosuximide
DrugBank: Ethosuximide (DB00593)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethosuximide given 3 times daily
Study: 780040
Drug: Single daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single daily dose regimen
Study: 28789780
Drug: IncobotulinumtoxinA (IncoA)
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: IncobotulinumtoxinA (IncoA) injection
Study: 23930743
Drug: Escitalopram (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (10 mg for patients ≤65 years; 5 mg for patients >65 years)
Study: 23930743
Drug: Problem-solving therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-solving therapy (PST, 12 total sessions)
Study: 16982785
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg extended-release ciprofloxacin
Study: 11377154
Drug: Propofol 6
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 6 microg/mL
Study: 11377154
Drug: Propofol 8
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 8 microg/mL
Study: 8566633
Drug: etodolac 400
Normalized name: etodolac 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: etodolac 400 mg
Study: 2598769
Drug: Ursodiol 250
Normalized name: ursodiol 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodiol 250 mg/day
Study: 2598769
Drug: Ursodiol 500
Normalized name: ursodiol 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodiol 500 mg/day
Study: 2598769
Drug: Ursodiol 750
Normalized name: ursodeoxycholate
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodiol 750 mg/day
Study: 2598769
Drug: Ursodiol administration
Normalized name: ursodeoxycholate
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodiol administration in patients with initial serum bilirubin levels > 2 mg/dl
Study: 28486043
Drug: Azacitidine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azacitidine (75 mg/m2/day on days 1 to 7 of a 28-day cycle)
Study: 28486043
Drug: Azacitidine plus
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine plus Lenalidomide (10 mg/day on days 1 to 21)
Study: 28486043
Drug: Azacitidine plus
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine plus Vorinostat (300 mg twice daily on days 3 to 9)
Study: 16986136
Drug: Intravesical instillation
Normalized name: ADSTILADRIN Suspension for Intravesical Instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical instillation of 100 ml capsaicin diluted in glucidic solvent (CG)
Study: 16455629
Drug: 89SrCl2 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 89SrCl2 therapy
Study: 12701977
Drug: Cisplatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (40 mg/m2) concurrent with radiotherapy
Study: 11013775
Drug: Morphine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (5 mg) injected periarticularly
Study: 8805740
Drug: Adenosine (0.140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine (0.140 mg/kg/min for 6 minutes)
Study: 8805740
Drug: Dipyridamole (0.142
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (0.142 mg/kg/min for 4 minutes)
Study: 1621888
Drug: Proguanil (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proguanil (200 mg/day) combined with dapsone (4 mg or 12.5 mg/day)
Study: 1621888
Drug: Pyrimethamine/dapsone (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrimethamine/dapsone (12.5 mg and 100 mg/week)
Study: 6150856
Drug: S3341 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: S3341 (2 mg)
Study: 2883104
Drug: Clonidine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.1 and 0.2 mg)
Study: 19731013
Drug: Exemestane 25
Normalized name: exemestane 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane 25 mg for 8 weeks
Study: 19731013
Drug: Anastrozole 1
Normalized name: anastrozole 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole 1 mg for 8 weeks
Study: 17606534
Drug: Oral, attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, attenuated monovalent G1[P8] human rotavirus vaccine (10^4.7 infectious units)
Study: 17606534
Drug: Oral, attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, attenuated monovalent G1[P8] human rotavirus vaccine (10^5.2 infectious units)
Study: 17606534
Drug: Oral, attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, attenuated monovalent G1[P8] human rotavirus vaccine (10^5.8 infectious units)
Study: 7774139
Drug: Intrapartum antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapartum antibiotics (group 1)
Study: 2321774
Drug: Epidural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural fentanyl (100 micrograms in 10 ml normal saline)
Study: 2321774
Drug: Epidural normal
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural normal saline (10 ml)
Study: 2321774
Drug: Epidural catheter
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural catheter with no solution injected
Study: 7359263
Drug: 7 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 mg/kg hydrocortisone intravenously every six hours
Study: 7359263
Drug: Salbutamol inhalations
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol inhalations and intravenous aminophylline therapy (common to both groups)
Study: 30670044
Drug: Remote cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote cognitive behaviour therapy (RCBT)
Study: 28644208
Drug: Whole Body
Normalized name: MaxiVision Whole Body Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole Body Vibration (WBV) during therapy sessions (S1, S2, S3) consisting of five upper and/or lower extremity exercises.
Study: 28644208
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard therapy alone) during therapy sessions (S1, S2, S3).
Study: 23982478
Drug: Intramyocardial injection
Normalized name: ALCOHOL 80 mL in 100 mL INTRAEPICARDIAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramyocardial injection of autologous bone marrow-derived ex vivo expanded mesenchymal stem cells (MSC)
Study: 30484987
Drug: Care Notebook
Approvals — FDA: no, EMA: no, PMDA: no
Description: Care Notebook intervention (self-monitoring QOL), completed once daily.
Study: 27876083
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment and usual care
Study: 27876083
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care without endovascular treatment
Study: 25050340
Drug: Fosaprepitant 150
Normalized name: fosaprepitant 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosaprepitant 150 mg i.v. (NK1 group)
Study: 25050340
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg i.v. (ONS group)
Study: 22207026
Drug: Subacromial patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subacromial patient-controlled analgesia (SA-PCA) with 0.5% ropivacaine at a rate of 2 ml/h and a patient-controlled bolus dose of 2 ml.
Study: 22207026
Drug: Intravenous patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous patient-controlled analgesia (IV-PCA).
Study: 19633051
Drug: Chemoendocrine adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoendocrine adjuvant therapy without goserelin in premenopausal patients with endocrine-responsive tumors
Study: 19633051
Drug: Adequate endocrine
Normalized name: Adequan
DrugBank: Polysulfated glycosaminoglycan (DB11538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adequate endocrine adjuvant therapy
Study: 16881941
Drug: Standard depression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard depression treatment plus literacy education
Study: 16881941
Drug: Standard depression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard depression treatment